Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

Name: Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC
Uploaded: 2017-09-21T20:35:00.000Z
Description: Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

September 21, 2017

Dominick Bosse, MD

Video

In Partnership With:

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

In a study of patients with mRCC with bone metastases, pazopanib (Votrient) or sorafenib (Nexavar) was combined with radium-223. Primary endpoints were safety, efficacy and bone turnover markers.